Andere Sprachen BioRestorative Therapies, Inc.

Aktien

A3C9XF

US0906556065

BRTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
1.365 ^USD	-6.51%		+9.20%	-21.55%

30.04.	BioRestorative Therapies, Inc. kündigt transformative Handelsvereinbarung mit Cartessa Aesthetics, LLC an	CI
16.04.	BioRestorative Therapies, Inc. gibt die FDA-Genehmigung für die Änderung des Protokolls der klinischen Phase-2-Studie mit BRTX-100 bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	30.04.
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	30.04.
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	30.04.
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	16.04.
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	16.04.
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16.04.
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16.04.
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08.04.
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08.04.
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	03.04.
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	01.04.
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	11.03.
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	14.02.
Top Midday Decliners	06.02.
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	06.02.
Top Premarket Decliners	06.02.
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	05.02.
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	05.02.
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	05.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioRestorative Therapies, Inc.

Aktien

A3C9XF

US0906556065

BRTX

Andere Sprachen

Filter